¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"somatic cell gene therapy"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëü, Ç÷±¸´ëü
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell-associated antibody
    ¼¼Æ÷¿¬°üÇ×ü
  • cell-bound antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-fixed antibody
    ¼¼Æ÷°áÇÕÇ×ü
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î¼º
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell membrane permeability
    ¼¼Æ÷¸·Åõ°ú¼º
  • cell surface receptor
    ¼¼Æ÷Ç¥¸é¼ö¿ëü
  • cell-associated virus
    ¼¼Æ÷ºÎÂø¹ÙÀÌ·¯½º
  • cell-mediated cytolysis
    ¼¼Æ÷¸Å°³¼¼Æ÷¿ëÇØ
  • cell-mediated cytotoxicity
    ¼¼Æ÷¸Å°³¼¼Æ÷µ¶¼º
  • cell-mediated hypersensitivity
    ¼¼Æ÷¸Å°³°ú¹Î
  • cell-mediated immunity
    ¼¼Æ÷¸Å°³¸é¿ª
  • cell-mediated reaction
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated response
    ¼¼Æ÷¸Å°³¹ÝÀÀ
  • cell-mediated immunodeficiency syndrome
    ¼¼Æ÷¸Å°³¸é¿ª°áÇÌÁõÈıº
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
  • funicular cell
    ÁÙ¼¼Æ÷, »è¼¼Æ÷(ßãá¬øà).
  • fusiform cell
    ¹æÃß¼¼Æ÷
  • fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • behavioral - cognitive therapy
    Çൿ(ÇàÅÂ)ÀÎÁöÀû Ä¡·á
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
  • behavioral therapy
    Çൿġ·á, Çൿ¿ä¹ý(ú¼ÔÑèþÛö)
  • biologic therapy
    À¯Àü»ý¹°ÇÐÀû Á¦Á¦¿ä¹ý(ßæÚªùÊîÜð²ð¥èþÛö).
  • blood component therapy
    Ç÷¾×¼ººÐ¿ä¹ý.
  • boost radiation therapy
    Ãß°¡¹æ»ç¼±Ä¡·á
  • boron-neutron capture therapy, BNCT
    º¸·ÐÁß¼ºÀÚÆ÷ȹ¿ä¹ý
  • bronchial hygiene therapy
    ±â°üÁö À§»ý¼ú
  • client-centered therapy
    ³»´ãÀÚÁß½ÉÀû Ä¡·á(ÕÎÓÈíºñéãýîÜö½èþ).
  • client-centered therapy
    ³»´ãÀÚÁß½ÉÄ¡·á
  • cognitive therapy
    ÀÎÁö¿ä¹ý(ìãò±èþÛö)
  • cognitive-behavioral therapy
    ÀÎÁö-Çൿ ¿ä¹ý(ìãò±ú¼ÔÑèþÛö)
  • cold therapy
    ÇÑ·©(ùÎÒ²) Ä¡·á(¹ý)(ö½Öû(Ûö))
  • coma therapy
    È¥¼ö¿ä¹ý(ûçá÷ÖûÛö)
  • combined modality therapy
    º´¿ëÄ¡·á¹ý
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • Glomus cell
    Å丮¼¼Æ÷
    [¿¾ ¿ë¾î] ±¸»ó¼¼Æ÷
  • Tendon cell
    ÈûÁÙ¼¼Æ÷
    [¿¾ ¿ë¾î] °Ç¼¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
PAG periaqueductal gray [matter]; polyacrylamide gel; pregnancy-associated globulin; proliferation-assoc...
PAGA proliferation-associated gene A
PHOX paired mesoderm homeobox [gene]
PMX paired mesoderm homeobox [gene]
RAG ragweed; recombination activating gene
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
3-DCRT Three-dimensional conformal radiation therapy
TT Thrombolytic therapy
WBRT Whole-brain radiation therapy
CMT combined modality therapy
CIT conventional insulin therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • clear cell acanthoma
    Åõ¸í ¼¼Æ÷ ±Ø¼¼Æ÷Á¾
  • clear cell hidradenoma
    Åõ¸í ¼¼Æ÷ ÇѼ±Á¾
  • clear cell sarcoma
    Åõ¸í ¼¼Æ÷ À°Á¾
  • cleared cell
    Åõ¸í ¼¼Æ÷
  • columnar cell carcinoma
    ¿øÁÖ ¼¼Æ÷ ¾ÏÁ¾
  • columnar epithelial cell
    ¿øÁÖ »óÇÇ ¼¼Æ÷
  • columns of cartilage cell
    ¿¬°ñ ¼¼Æ÷ ±âµÕ, ¿¬°ñ ¼¼Æ÷ÁÖ
  • committed cell
    À§Å¹ ¼¼Æ÷
    ¾î¶² ƯÁ¤ÇÑ Ç׿ø °áÁ¤±º¿¡ ´ëÇØ¼­ ƯÀÌÀûÀÎ Ç×ü¸¦ »ý»êÇϵµ·Ï À§Å¹µÈ ¼¼Æ÷. À§Å¹ ¼¼Æ÷¿¡´Â Ç׿øÀÌ Á¢Ã˵Ǿú´ø ÀûÀÌ ÀÖ´Â ¼¼Æ÷, ±â¾ï¼¼Æ÷, ¹× Ç×ü»ý»ê ¼¼Æ÷ µîÀÌ Æ÷ÇԵȴÙ.
  • companion cell
    µ¿¹Ý ¼¼Æ÷
  • cone cell
    ¿ø»Ô ¼¼Æ÷, Ãß»óü ¼¼Æ÷, ¿øÃß ¼¼Æ÷
    ôÃßµ¿¹°ÀÇ ¸Á¸·ÀÇ °¡Àå ¾ÈÂÊ¿¡ ÀÖ´Â ½Ã¼¼Æ÷ÀÇ ÀÏÁ¾. Ãßü ¼¼Æ÷, Ãß»óü ¼¼Æ÷¶ó°íµµ ÇÑ´Ù. ½Ã¼¼Æ÷´Â ±× ÇüÅÂ¿Í ±â´É»ó¿¡ µû¶ó ¿øÃß ¼¼Æ÷¿Í °£»ó ¼¼Æ÷ÀÇ 2Á¾À¸·Î ±¸º°µÈ´Ù. ¿øÃß ¼¼Æ÷´Â ºñ±³Àû ¹àÀº °÷¿¡¼­ ¹°Ã¼¸¦ º¸´Â ÀÏ, »öÀ» ½Äº°
  • congenital granular cell epulis
    ¼±ÃµÀû °ú¸³¼¼Æ÷¼º Ä¡ÀºÁ¾
  • cornified epithelial cell
    °¢È­ »óÇÇ ¼¼Æ÷
  • cortical cell
    ÇÇÁú ¼¼Æ÷
  • crystal cell
    °áÁ¤ ¼¼Æ÷
    ³»ºÎ¿¡ °¢Á¾ °áÁ¤À» ÇÔÀ¯ÇÏ´Â ¼¼Æ÷. ºÐºñ ¼¼Æ÷ÀÇ ÀÏÁ¾À¸·Î, º¸Åë ÁÖÀ§ÀÇ ¼¼Æ÷¿Í ¸ð¾çÀÌ ¾à°£ ´Ù¸£´Ù. Á¤¹æÁ¤°è ¶Ç´Â ´Ü»çÁ¤°è·Î µÈ Å« ¿Á»ì»ê Ä®½· °áÁ¤À» º£°í´Ï¾Æ¼Ó µî ½Ä¹°Á¶Á÷ ³»¿¡¼­ ÈçÈ÷ º¼ ¼ö ÀÖ´Ù. ¶§·Î´Â ¼ÒÇüÀÇ °áÁ¤ÀÌ ´Ù¼ö ±ºÁýÇÏ¿© °áÁ¤»ç°¡ µÇ°Å³ª ħ»ó °áÁ¤ÀÌ ´Ù¼ö ÆòÇàÀ¸·Î ¹è¿­µÇ¾î °áÁ¤ ¼ÓÀÌ µÈ´Ù
  • cutaneous B cell lymphoma
    ÇǺΠB ¼¼Æ÷ ¸²ÇÁÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
gene probe A biomolecule that islabelled with radioactive isotopes or with a fluorescent marker that selectively binds to a specific gene so it can be isolated or identified.
(09 Oct 1997)
gene product The biochemical material, either RNA or protein, resulting from expression of a gene. The amount of gene product is used to measure how active a gene is, abnormal amounts can be correlated with disease-causing alleles.
(09 Oct 1997)
gene products, env Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease.
(12 Dec 1998)
gene products, gag Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen.
(12 Dec 1998)
gene products, nef Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor.
(12 Dec 1998)
gene products, pol Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase.
(12 Dec 1998)
gene products, rev Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion.
(12 Dec 1998)
gene products, rex Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr.
(12 Dec 1998)
gene products, tat Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription.
(12 Dec 1998)
gene products, tax Transcriptional trans-acting proteins of the promoter elements found in the long-terminal repeats (ltr) of HTLV-I and HTLV-II. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the ltr.
(12 Dec 1998)
gene products, vif A 23 kD regulatory protein important for virion infectivity in HIV. The protein is found in the cytoplasm of HIV-infected cells and is not absolutely required for virion formation.
(12 Dec 1998)
gene products, vpr Trans-acting proteins which accelerate virus replication in HIV. The vpr proteins act in trans to increase the levels of HIV specified proteins. Vpr is short for viral protein r, where r is undefined.
(12 Dec 1998)
gene products, vpu Non-glycosylated, membrane-associated, 16 kD proteins which are expressed in large amounts in cells infected with HIV-1. The proteins are required for efficient virion maturation and release. They are not present in HIV-2 nor in siv. Vpu is short for viral protein u, with u undefined.
(12 Dec 1998)
gene rearrangement A structural alteration of a chromosome that causes a change in the orderof its loci.
(09 Oct 1997)
gene rearrangement, b-lymphocyte Ordered rearrangement of b-lymphocyte variable gene regions coding for the immunoglobulin chains, thereby contributing to antibody diversity. It occurs during the differentiation of the immature b-lymphocyte.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á